VCKA Stock Price, Vickers Vantage Corp. I Quote, Chart

Market Summary

USD0.86+0.01

Market Closed

1.18%

VCKA Stock Price

View Fullscreen

VCKA RSI Chart

VCKA Valuation

Market Cap

141.3M

Price/Earnings (Trailing)

-1.24

Price/Sales (Trailing)

3.02

EV/EBITDA

-1.33

Price/Free Cashflow

-6.81

VCKA Price/Sales (Trailing)

VCKA Profitability

Operating Margin

66.45%

EBT Margin

-244.57%

Return on Equity

66.11%

Return on Assets

-112.85%

Free Cashflow Yield

-14.68%

VCKA Fundamentals

VCKA Revenue

Revenue (TTM)

46.7M

Rev. Growth (Yr)

12.95%

Rev. Growth (Qtr)

33.06%

VCKA Earnings

Earnings (TTM)

-114.3M

Earnings Growth (Yr)

-19.66%

Earnings Growth (Qtr)

39.77%

Breaking Down VCKA Revenue

Last 7 days

-26.7%

Last 30 days

-41.8%

Last 90 days

-46.2%

Trailing 12 Months

-84.9%

How does VCKA drawdown profile look like?

VCKA Financial Health

Current Ratio

0.19

VCKA Investor Care

Buy Backs (1Y)

29.24%

Diluted EPS (TTM)

-1.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	41.8M	46.5M	45.2M	46.7M
2022	32.3M	33.4M	34.4M	38.0M
2021	25.5M	27.4M	29.4M	31.3M
2020	0	0	0	23.6M
2019	0	0	0	21.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold VCKA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Nov 10, 2022	Salient Capital Advisors, LLC	sold off	-100	-358,000	-	-%

Are Funds Buying or Selling VCKA?

Are funds buying VCKA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VCKA

No. of Funds

Unveiling Vickers Vantage Corp. I's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 05, 2024	sclx stock acquisition jv llc	36.4%	89,616,299	SC 13D/A
Jan 31, 2024	sclx stock acquisition jv llc	38.2%	89,616,299	SC 13D/A
Sep 29, 2023	sclx stock acquisition jv llc	39.3%	89,616,299	SC 13D
Sep 26, 2023	sorrento therapeutics, inc.	1.3%	1,917,210	SC 13D/A
Aug 15, 2023	sorrento therapeutics, inc.	43.3%	95,533,509	SC 13D/A
Mar 03, 2023	sorrento therapeutics, inc.	44.2%	95,533,509	SC 13D/A
Feb 13, 2023	hudson bay capital management lp	0%	0	SC 13G/A
Jan 23, 2023	sorrento therapeutics, inc.	45.5%	95,533,509	SC 13D/A
Dec 09, 2022	karpus management, inc.	0%	0	SC 13G/A
Nov 17, 2022	sorrento therapeutics, inc.	96.3%	167,887,687	SC 13D

Recent SEC filings of Vickers Vantage Corp. I

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	8-K	Current Report
Apr 05, 2024	424B3	Prospectus Filed
Apr 05, 2024	424B3	Prospectus Filed
Apr 05, 2024	8-K	Current Report
Apr 02, 2024	424B3	Prospectus Filed
Apr 02, 2024	424B3	Prospectus Filed
Mar 29, 2024	EFFECT	EFFECT
Mar 29, 2024	EFFECT	EFFECT
Mar 29, 2024	EFFECT	EFFECT
Mar 29, 2024	EFFECT	EFFECT

Vickers Vantage Corp. I News

Latest updates

Vickers Vantage Corp. I Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Revenue	33.1%	13,462,000	10,117,000	12,582,000	10,582,000	11,919,000	11,377,000	7,926,000	6,812,000	8,263,000	10,108,667	11,954,333	13,800,000	-	-
Cost Of Revenue	33.3%	4,521,000	3,392,000	4,177,000	3,591,000	4,513,000	3,611,000	1,529,000	1,144,000	1,085,000	-	-	-	-	-
Operating Expenses	-35.0%	31,801,000	48,922,000	35,396,000	36,055,000	31,660,000	21,993,000	19,397,000	15,618,000	42,607,179	283,346	172,140	165,156	420	-
S&GA Expenses	-41.8%	23,520,000	40,431,000	26,989,000	28,701,000	23,524,000	16,119,000	14,344,000	10,908,000	14,490,000	-	-	-	-	-
R&D Expenses	-32.9%	2,734,000	4,072,000	3,204,000	2,736,000	2,597,000	1,237,000	2,589,000	2,631,000	2,170,000	-	-	-	-	-
EBITDA Margin	0.4%	-2.20	-2.21	-0.93	-0.83	-0.35	-1.13	-2.44	-2.25	-2.33	-1.04	-1.12	-1.20	-	-
Interest Expenses	7.4%	551,000	513,000	-	-	4,369,127	1,858,000	8,280	7,466	3,147,000	-	-	-	-	-
Income Taxes	-	8,000	-	-3,000	8,000	40,000	-11,000	-28,000	3,000	-5,000	-	-	-	-	-
Earnings Before Taxes	39.8%	-21,392,000	-35,529,000	-26,652,000	-30,745,000	-17,844,000	21,490,000	-17,866,000	-9,140,000	-41,970,000	-	-	-	-	-
EBT Margin	0.2%	-2.45	-2.45	-1.16	-1.08	-0.61	-1.38	-2.65	-2.73	-2.82	-1.62	-1.73	-1.87	-	-
Net Income	39.8%	-21,400,000	-35,529,000	-26,649,000	-30,753,000	-17,884,000	21,501,000	-17,838,000	-9,143,000	-65,019,876	-1,444,352	-233,749	1,328,853	-420	-
Net Income Margin	0.2%	-2.45	-2.45	-1.16	-1.08	-0.61	-2.05	-2.80	-2.35	-2.09	-0.01	0.04	0.05	-	-
Free Cashflow	-191.7%	-5,391,000	5,879,000	-13,473,000	-7,744,000	-725,000	2,526,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	25.8%	101	81.00	126	86.00	87.00	89.00	142	141	78.00	140	140	140	82.00
Current Assets	83.6%	47.00	25.00	69.00	31.00	30.00	31.00	1.00	1.00	23.00	0.00	0.00	1.00	22.00
Cash Equivalents	100.7%	4.00	2.00	34.00	5.00	2.00	2.00	7.00	34.00	4.00	4.00	0.00	0.00	5.00
Inventory	6.9%	4.00	4.00	3.00	2.00	1.00	1.00	-	-	3.00	-	-	-	1.00
Net PPE	-6.1%	1.00	1.00	1.00	1.00	1.00	1.00	-	-	1.00	-	-	-	1.00
Goodwill	0%	14.00	14.00	13.00	14.00	14.00	13.00	-	-	13.00	-	-	-	13.00
Liabilities	12.8%	274	243	116	75.00	50.00	318	53.00	177	302	10.00	9.00	9.00	223
Current Liabilities	9.5%	250	229	104	65.00	45.00	251	1.00	0.00	169	0.00	0.00	0.00	78.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	38.00	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	72.00	-	-	-	92.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	38.00	-	-	-	16.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	72.00	-	-	-	92.00
Shareholder's Equity	-Infinity%	-172	-	10.00	11.00	36.00	-	-	-	-223	-	5.00	5.00	0.00
Retained Earnings	-4.6%	-490	-468	-433	-406	-375	-358	-10.77	-10.54	-352	-9.83	1.00	1.00	-264
Additional Paid-In Capital	2.8%	408	397	444	418	412	129	-	-	129	-	4.00	4.00	122
Shares Outstanding	6.3%	100	94.00	149	146	141	133	133	-	133	3.00	16.00	-	-
Float	-	-	-	480	-	-	-	99.00	-	-	-	137	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-191.4%	-5,390	5,900	-13,473	-7,744	-725	2,533	-12,335	-10,731	-5,957	-21,908	-551	-494	-420*	-	-
Share Based Compensation	7.9%	3,783	3,506	3,587	3,720	1,253	1,235	1,437	1,355	1,454	-	-	-	-	-	-
Cashflow From Investing	-7.7%	-167	-155	-	-	-	-7.00	-1,025	-1,035	-	209,070	-139,380	-139,380	-	-	-
Cashflow From Financing	121.4%	8,306	-38,891	43,538	10,629	426	-6,868	-12,347	39,960	6,090	-188,165	140,159	140,159	-47.93	-	-

VCKA Income Statement

2023-12-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 46,743	$ 38,034	$ 31,317
Operating costs and expenses:
Cost of revenue	15,681	10,797	3,634
Research and development	12,746	9,054	9,201
Selling, general and administrative	119,641	64,895	50,582
Intangible amortization	4,106	3,922	3,738
Total operating costs and expenses	152,174	88,668	67,155
Loss from operations	(105,431)	(50,634)	(35,838)
Other (income) expense:
Loss (gain) on derivative liability	512	(8,310)	300
Change in fair value of debt and liability instruments	7,189	0	0
Gain on debt extinguishment, net	0	(28,634)	12,463
Scilex Pharma Notes principal increase	0	0	28,000
Interest expense, net	1,068	9,604	11,764
Loss on foreign currency exchange	118	66	54
Total other (income) expense	8,887	(27,274)	52,581
Loss before income taxes	(114,318)	(23,360)	(88,419)
Income tax expense	13	4	5
Net loss	$ (114,331)	$ (23,364)	$ (88,424)
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders - basic	$ (1.28)	$ (0.17)	$ (0.67)
Net loss per share attributable to common stockholders - diluted	$ (1.28)	$ (0.17)	$ (0.67)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted average number of shares during the period-basic	130,298	134,226	132,858
Weighted average number of shares during the period -diluted	130,298	134,226	132,858

VCKA Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,921	$ 2,184
Accounts receivable, net	34,597	21,236
Inventory	4,214	1,378
Prepaid expenses and other	4,049	4,810
Total current assets:	46,781	29,608
Property and equipment, net	722	772
Operating lease right-of-use asset	2,943	1,131
Intangibles, net	36,485	40,591
Goodwill	13,481	13,481
Other long term assets	897	944
Total assets	101,309	86,527
Current liabilities:
Accounts payable	40,954	8,450
Accrued payroll	2,681	1,354
Accrued rebates and fees	89,658	30,893
Accrued expenses	7,408	3,136
Current portion of deferred consideration	491	264
Debt, current	108,429	0
Current portion of operating lease liabilities	759	745
Total current liabilities:	250,380	44,842
Long-term portion of deferred consideration	2,895	3,387
Debt, net of issuance costs	17,038	0
Derivative liabilities	1,518	1,231
Operating lease liabilities	2,237	665
Other long-term liabilities	179	163
Total liabilities	274,247	50,288
Commitments and contingencies (See Note 11)
Stockholders' (deficit) equity:
Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	0	3
Common stock, $0.0001 par value, 740,000,000 shares authorized; 160,084,250 shares issued and 100,015,665 shares outstanding as of December 31, 2023; 141,348,856 shares issued and outstanding as of December 31, 2022	16	14
Additional paid-in capital	407,813	412,136
Accumulated deficit	(490,245)	(375,914)
Treasury stock, at cost; 60,068,585 shares and nil shares as of September 30, 2023 and December 31, 2022, respectively	(90,522)	0
Total stockholders' (deficit) equity	(172,938)	36,239
Total liabilities and stockholders' (deficit) equity	$ 101,309	$ 86,527

About Vickers Vantage Corp. I

0

WEBSITE	vickersvantage.com

Vickers Vantage Corp. I Frequently Asked Questions

What is the ticker symbol for Vickers Vantage Corp. I? What does VCKA stand for in stocks?

VCKA is the stock ticker symbol of Vickers Vantage Corp. I. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vickers Vantage Corp. I (VCKA)?

As of Wed Apr 24 2024, market cap of Vickers Vantage Corp. I is 141.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCKA stock?

You can check VCKA's fair value in chart for subscribers.

What is the fair value of VCKA stock?

You can check VCKA's fair value in chart for subscribers. The fair value of Vickers Vantage Corp. I is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vickers Vantage Corp. I is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VCKA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vickers Vantage Corp. I a good stock to buy?

The fair value guage provides a quick view whether VCKA is over valued or under valued. Whether Vickers Vantage Corp. I is cheap or expensive depends on the assumptions which impact Vickers Vantage Corp. I's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCKA.

What is Vickers Vantage Corp. I's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, VCKA's PE ratio (Price to Earnings) is -1.24 and Price to Sales (PS) ratio is 3.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCKA PE ratio will change depending on the future growth rate expectations of investors.